Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2001 Nov;45(11):3276-8.
doi: 10.1128/AAC.45.11.3276-3278.2001.

In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin

A Gikas  1 , I Spyridaki, E Scoulica, A Psaroulaki, Y Tselentis
Affiliations
Comparative Study

In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin

A Gikas et al. Antimicrob Agents Chemother. 2001 Nov.

Abstract

The in vitro susceptibility to linezolid shown by nine Greek isolates of Coxiella burnetii derived from patients with acute Q fever was investigated. MICs of linezolid were compared with those of pefloxacin, ciprofloxacin, ofloxacin, trovafloxacin, doxycycline, and clarithromycin using the shell vial assay. MICs of linezolid and clarithromycin ranged from 2 to 4 microg/ml; those of doxycycline, trovafloxacin, and ofloxacin ranged from 1 to 2 microg/ml; those of pefloxacin ranged from 1 to 4 microg/ml; and those of ciprofloxacin ranged from 4 to 8 microg/ml. Linezolid was effective in controlling intracellular parasites in cultures of Vero cells infected by C. burnetii. No bactericidal activity by linezolid was obtained against C. burnetii at 8 microg/ml.

PubMed Disclaimer

References

    1. Clemett D, Markham A. Linezolid. Drugs. 2000;59:815–827. - PubMed
    1. Craig W A. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995;22:89–96. - PubMed
    1. Diekema D I, Jones R N. Oxazolidinones: a review. Drugs. 2000;59:7–16. - PubMed
    1. Gikas A, Spyridaki I, Psaroulaki A, Kofterithis D, Tselentis Y. In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. Antimicrob Agents Chemother. 1998;42:2747–2748. - PMC - PubMed
    1. Green S L, Maddox J C, Huttenbach E D. Linezolid and reversible myelosuppression. JAMA. 2001;285:1291. - PubMed

Publication types